Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Inclusion Criteria: * Male or Female patients, age \>18 * Life expectancy \> 6 months * Histological proven, metastatic, or locally advanced and non-operable, non- pre-treated GIST. * Patients having never received any tyrosine kinase inhibitor, including as adjuvant therapy * C-Kit (CD117) positive tumors detected immuno-histochemically * Measurable tumor lesions with longest diameter \>20 mm using conventional techniques or \>10 mm with spiral CT scan Exclusion Criteria: * Documented allergy to the similar drug of AB1010 * Inadequate organ function * Patients with a history of any other malignancy